Pliant Therapeutics (NASDAQ:PLRX) vs. Nanobiotix (NASDAQ:NBTX) Critical Contrast

Nanobiotix (NASDAQ:NBTX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Risk and Volatility

Nanobiotix has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Nanobiotix and Pliant Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1	1	4	0	2.50
Pliant Therapeutics	2	2	1	0	1.80

Nanobiotix presently has a consensus target price of $37.33, suggesting a potential downside of 2.32%. Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 185.71%. Given Pliant Therapeutics’ higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Nanobiotix.

Valuation & Earnings

This table compares Nanobiotix and Pliant Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64 million	65.27	-$27.11 million	N/A	N/A
Pliant Therapeutics	N/A	N/A	-$149.34 million	($1.84)	-0.57

Nanobiotix has higher revenue and earnings than Pliant Therapeutics.

Profitability

This table compares Nanobiotix and Pliant Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Pliant Therapeutics	N/A	-58.11%	-44.37%

Institutional and Insider Ownership

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Nanobiotix beats Pliant Therapeutics on 6 of the 10 factors compared between the two stocks.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.